Orrstown Financial Services Inc. Makes New Investment in Boston Scientific Corporation $BSX

Key Points

• Orrstown Financial Services Inc. acquired 2,635 shares of Boston Scientific Corporation, valued at approximately $283,000, highlighting growing institutional interest in the stock.
• Boston Scientific reported a strong earnings quarter with an EPS of $0.75, exceeding expectations, along with revenue of $5.06 billion, which is a 22.8% increase year-over-year.
• Analysts maintain a positive outlook on Boston Scientific, with a consensus rating of "Buy" and a target price averaging $118.04.

Orrstown Financial Services Inc. bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,635 shares of the medical equipment provider's stock, valued at approximately $283,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Sunbeam Capital Management LLC acquired a new stake in Boston Scientific in the fourth quarter worth approximately $26,000. 1248 Management LLC acquired a new stake in shares of Boston Scientific during the 1st quarter valued at $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific during the 1st quarter valued at $27,000. Ameriflex Group Inc. acquired a new stake in shares of Boston Scientific during the 4th quarter valued at $31,000. Finally, Fourth Dimension Wealth LLC acquired a new stake in shares of Boston Scientific during the 4th quarter valued at $36,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BSX. Raymond James Financial increased their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 24th. BTIG Research reiterated a "buy" rating and set a $127.00 price objective on shares of Boston Scientific in a research report on Tuesday. Needham & Company LLC reiterated a "buy" rating and set a $121.00 price objective on shares of Boston Scientific in a research report on Friday. Barclays increased their price objective on Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Finally, Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $118.17.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded up $0.77 during midday trading on Tuesday, hitting $97.80. The company's stock had a trading volume of 8,814,214 shares, compared to its average volume of 7,726,885. The stock has a market capitalization of $144.92 billion, a price-to-earnings ratio of 58.20, a PEG ratio of 2.36 and a beta of 0.65. The stock's 50 day simple moving average is $104.25 and its 200 day simple moving average is $102.08. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's revenue was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $18,397,457 in the last three months. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.